Analysts think SCPH stock price could increase by 307%
Aug 02, 2024, 6:25 AM
7.04%
What does SCPH do
scPharmaceuticals, Inc., based in Burlington, Massachusetts, focuses on developing subcutaneous pharmaceutical products like FUROSCIX for conditions such as congestive heart failure and infection treatments. The company, founded with 96 employees, went public in 2017 and prioritizes healthcare cost reduction and improved health outcomes.
8 analysts think SCPH stock price will increase by 307.14%. The current median analyst target is $19.38 compared to a current stock price of $4.76. The lowest analysts target is $16.16 and the highest analyst target is $26.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
